Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

A Phase I/II, Dose-Escalation and Dose-Expansion Study of CS5006, in Participants With Advanced Solid Tumors

10 november 2026 uppdaterad av: CStone Pharmaceuticals

A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activities of CS5006, a Novel Antibody-Drug Conjugate Targeting ITGB4, in Participants With Advanced Solid Tumors

This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS5006 in participants with advanced solid tumors. The study comprises of a Phase I dose escalation and Phase II dose expansion.

Studieöversikt

Status

Har inte rekryterat ännu

Intervention / Behandling

Detaljerad beskrivning

In Phase I, participants with specified advanced epithelial solid tumors will be enrolled to establish the MTD, if any, and tentative RP2D(s) of CS5006. The specified advanced epithelial solid tumors included but not limited non-small cell lung cancer (NSCLC), colorectal cancer (CRC), squamous cell carcinoma of head and neck (HNSCC), urothelial carcinoma (UC), triple-negative breast cancer (TNBC), cervical cancer (CC), esophageal squamous cell carcinoma (ESCC) , endometrial cancer, ovarian cancer (OC), renal cell carcinoma (RCC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), biliary tract cancer (BTC), gastric cancer (GC), pancreatic cancer(PDAC) and prostate cancer(PCa).

In Phase II, participants with selected advanced solid tumors - including locally advanced or metastatic non-small cell lung cancers (AGA [actionable genomic alterations] negative NSCLC, Cohort 1; EGFR-mutant NSCLC, Cohort 2; NSCLC with actionable driver alterations other than EGFR-sensitive mutations, Cohort 3; colorectal cancer (CRC), Cohort 4; squamous cell carcinoma of head and neck (HNSCC), Cohort 5; urothelial carcinoma (UC), Cohort 6; cervical cancer (CC), Cohort 7; esophageal squamous cell carcinoma (ESCC), Cohort 8 - will be enrolled to further assess the efficacy, safety, tolerability, pharmacokinetics of CS5006 at the tentative RP2D(s).

Studietyp

Interventionell

Inskrivning (Beräknad)

310

Fas

  • Fas 2
  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • New South Wales
      • North Ryde, New South Wales, Australien, 2109
        • Macquarie University
        • Huvudutredare:
          • John Park, Dr
      • Randwick, New South Wales, Australien, 2031
        • Scientia Clinical Research Ltd
        • Huvudutredare:
          • Charlotte lemech, Dr
    • Victoria
      • Clayton, Victoria, Australien, 3168
        • Monash Medical Centre
        • Huvudutredare:
          • Sophia Frentzas, Dr
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200123
        • Shanghai East Hospital
        • Huvudutredare:
          • Caicun Zhou

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Evidence of a personally signed and dated informed consent document.
  • Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  • Being ≥ 18 years of age on the day of signing informed consent.
  • Pathologically or cytologically confirmed, unresectable advanced solid tumors.
  • Participants must have at least one measurable lesion according to RECIST Version1.1.
  • Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1.
  • Adequate organ function.
  • Life expectancy ≥ 3 months.
  • Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 180 days after the last study drug administration

Exclusion Criteria:

  • Has disease that is suitable for local treatment administered with curative intent.
  • Has a history of a second malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured.
  • Known primary central nervous system (CNS) tumor or solid tumor CNS metastasis that is symptomatic, untreated, or requires therapy.
  • Has life-threatening bleeding event or severe bleeding within 3 months prior to first dose.
  • Has uncontrolled pleural effusion, pericardial effusion, or ascites.
  • Has immune deficient disease or received systemic immunosuppressive treatment.
  • Has intestinal obstruction,or history of inflammatory bowel disease,or chronic diarrhea.
  • Has history of (non-infectious) interstitial lung disease/pneumonitis that required steroids.
  • Has active infections requiring systemic therapy.
  • Has significant cardiovascular disease or cerebrovascular accident within specified timeframes prior to first dose.
  • Insufficient washout from prior anti-tumor therapy.
  • Received live vaccine within 28 days prior to first dose.
  • History of allogeneic organ or hematopoietic stem cell transplantation.
  • History of hypersensitivity to excipients of study drug or any monoclonal antibody.
  • Any toxic effects of prior therapy unresolved to Grade ≤1.
  • Pregnant or breastfeeding women.
  • Other acute or chronic medical or psychiatric conditions that may increase risk or interfere with study results, in the investigator's judgment.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Icke-randomiserad
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Dose Escalation

Participants will be administered escalating doses of CS5006.

CS5006 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W).

Experimentell: Dose Expansion

Participants will be administered the recommended dose(s) of CS5006 according to dose-escalation data.

CS5006 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W).

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
[Dosexpansion] Objektiv svarsfrekvens (ORR) utvärderad av utredare enligt RECIST v1.1
Tidsram: Upp till cirka 2 år
Upp till cirka 2 år
[Dose Escalation] The incidence and severity of adverse events (AEs)
Tidsram: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation] Maximum tolerated dose (MTD) of CS5006
Tidsram: Cycle 1 (Up to 21 Days)

Participants will receive CS5006 via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W). The MTD will be determined, if any, by the number of participants who experience a dose limiting toxicity (DLT).

Cycle 1 (Up to 21 Days)
[Dose Escalation] Tentative recommended Phase II dose (RP2D) of CS5006
Tidsram: Up to approximately 2 years

The selection of tentative RP2D will be based on consideration of overall safety information together with available pharmacokinetic, pharmacodynamic, and efficacy data. The tentative RP2D may be the MTD or a lower dose within the tolerable dose range.

Up to approximately 2 years

Sekundära resultatmått

Resultatmått
Tidsram
[Doseskalering] Objektiv svarsfrekvens (ORR) utvärderad av utredare enligt RECIST v1.1
Tidsram: Upp till cirka 2 år
Upp till cirka 2 år
[Dose Escalation & Expansion] Area under the curve (AUC) of CS5007
Tidsram: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Duration of response (DOR) evaluated by investigators per RECIST v1.1
Tidsram: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Disease control rate (DCR) evaluated by investigators per RECIST v1.1
Tidsram: Up to approximately 2 years
Up to approximately 2 years
[Dose Expansion] The incidence and severity of adverse events (AEs)
Tidsram: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Maximum concentration (Cmax) of CS5006
Tidsram: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Time to maximum concentration (Tmax) of CS5006
Tidsram: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Elimination half-life (t1/2) of CS5006
Tidsram: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Clearance (CL) of CS5006
Tidsram: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Volume of distribution (Vz) of CS5006
Tidsram: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Trough concentration (Ctrough) of CS5006
Tidsram: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Accumulation ratio (R) of CS5006
Tidsram: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Number of participants with anti-CS5006 antibodies
Tidsram: Up to approximately 2 years
Up to approximately 2 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 december 2026

Primärt slutförande (Beräknad)

1 juli 2029

Avslutad studie (Beräknad)

1 juli 2029

Studieregistreringsdatum

Först inskickad

10 november 2026

Först inskickad som uppfyllde QC-kriterierna

10 november 2026

Första postat (Faktisk)

16 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

16 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

10 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • CS5006-101

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera